CN Patent

CN104418847A — 4-(6-脱氧-β-D-吡喃葡萄糖基)-2-[5-(4-氟苯基)噻吩-2-甲基]-1-甲基苯的制备工艺

Assigned to Tianjin Institute of Pharmaceutical Research Co Ltd · Expires 2015-03-18 · 11y expired

What this patent protects

4-(6-脱氧-β-D-吡喃葡萄糖基)-2-[5-(4-氟苯基)噻吩-2-甲基]-1-甲基苯的制备工艺。本发明公开了一种可以用来制备治疗2型糖尿病药物的脱氧C-葡萄糖苷类SGLT2抑制剂CD-6的制备方法，该方法具有步骤短、成本低、适合大规模工业化的特点。其中X选自Br和I。

USPTO Abstract

4-(6-脱氧-β-D-吡喃葡萄糖基)-2-[5-(4-氟苯基)噻吩-2-甲基]-1-甲基苯的制备工艺。本发明公开了一种可以用来制备治疗2型糖尿病药物的脱氧C-葡萄糖苷类SGLT2抑制剂CD-6的制备方法，该方法具有步骤短、成本低、适合大规模工业化的特点。其中X选自Br和I。

Drugs covered by this patent

Patent Metadata

Patent number
CN104418847A
Jurisdiction
CN
Classification
—
Expires
2015-03-18
Drug substance claim
No
Drug product claim
No
Assignee
Tianjin Institute of Pharmaceutical Research Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.